@Angus_Fierce profile picture
Angus Liu @Angus_Fierce

Biopharma reporter @FiercePharma & @FierceBiotech. Medill MSJ 16

Joined November 2013
  • Tweets 119
  • Following 646
  • Followers 786
2 Photos and videos
Thanks, Jacob. Means a lot coming from a fellow journalist whose work I admire.
Jacob Plieth
@JacobPlieth
May 31
V nice story from @Angus_Fierce on trial design differences & changes for PD(L)1xVEGF bispecifics fiercebiotech.com/biotech/ne… $BNTX $PFE $BMY
1
77
#ASCO26: For Akeso's HARMONi-6, ivonescimab's 34% overall survival improvement versus PD-1 inhibitor in their chemo combos in first-line squamous NSCLC draws both hope and scrutiny at #ASCO2026 fiercepharma.com/pharma/asco…

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by...

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its...

fiercepharma.com
1
1
4
1,950
Angus Liu retweeted
FierceBiotech
@FierceBiotech
Apr 17
Merck's first PD-1xVEGF bispecific data are here: 55% unconfirmed ORR in a small group of first-line NSCLC patients #AACR26 fiercebiotech.com/biotech/me…

AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans

More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. | More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the...

fiercebiotech.com
14
89
15,163
The FDA's press release says zongertinib's application was FILED on Jan. 13, 2026. But Boehringer told us that they actually completed the package under real-time oncology review on Nov. 14, 2025, and that it was ACCEPTED on Jan. 13.
Stephen V Liu, MD
@StephenVLiu
Feb 26
A new first line standard of care for HER2 mutant NSCLC? Zongertinib receives accelerated approval as initial therapy based on Beamion LUNG-1 trial with 1L RR 76%. Part of the new FDA voucher program, approval granted 44 days after filing! fda.gov/news-events/press-an…
1
1
3
501
In other words, FDA still took the full standard 60-day filing review period for a CNPV, even though this is an sNDA of an existing drug filed under RTOR, which means the review should have started before the entire submission package was completed.
3
97
FDA unveils ‘plausible mechanism pathway,’ a new approach that could trigger a seismic shift in how bespoke gene editing therapies are developed and approved. fiercebiotech.com/biotech/fd…

UPDATED: Prasad, Makary unveil new FDA path for accelerating custom gene editing therapies

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therap |...

fiercebiotech.com
1
111
Was just wondering what Vivek's been up to.
The Hill
@thehill
17 Feb 2025
Vivek Ramaswamy set to launch Ohio governor bid on Feb. 24 trib.al/8DJ4C6p
1
329
... Yunchan Lim ... Rach 2 ... 😭
This tweet is unavailable
1
581
Angus Liu retweeted
FiercePharma
@FiercePharma
8 Sep 2024
Akeso, Summit's ivonescimab crushes Merck's Keytruda in China study, signaling potential new standard of care in lung cancer #WCLC24 fiercepharma.com/pharma/akes…

Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology...

fiercepharma.com
8
14
3,169
Angus Liu retweeted
FiercePharma
@FiercePharma
14 Aug 2024
Before approving Amgen's breakthrough lung cancer med Imdelltra, FDA flagged 'a large number' of missing adverse events from a pivotal trial. fiercepharma.com/pharma/appr…

To approve Amgen's lung cancer med Imdelltra, FDA saw past 'large number' of missing adverse events

When the FDA approved Amgen’s Imdelltra in May, the T-cell engager was hailed as a breakthrough for the treatment of small cell lung cancer (SCLC) and as the first DLL3-targeting therapy of potenti |...

fiercepharma.com
1
8
13
2,927
Angus Liu retweeted
FiercePharma
@FiercePharma
24 May 2024
Eli Lilly invests additional $5.3B for production of diabetes, obesity drugs in Indiana fiercepharma.com/manufacturi…

Eli Lilly invests additional $5.3B for production of diabetes, obesity drugs in Indiana

Since scoring approval two years ago for its next-generation diabetes treatment Mounjaro (tirzepatide), Eli Lilly has been playing catch up with market leader Novo Nordisk. | Eli Lilly will invest an...

fiercepharma.com
7
14
3,377
Angus Liu retweeted
FiercePharma
@FiercePharma
1 May 2024
WuXi Biologics has quietly withdrawn from the BIO International Convention 2024 amid worsening geopolitical tensions fiercepharma.com/pharma/wuxi…

WuXi Biologics withdraws from 2024 BIO convention amid worsening geopolitical tensions

Amid a U.S. | WuXi Biologics has quietly pulled out of the 2024 BIO International Convention in June. The company's withdrawal from the convention comes at a point of heightened tension between...

fiercepharma.com
2
13
23
9,210
More background on the FDA's first-of-its-kind, confirmatory trial-related CRL for Regeneron. fiercebiotech.com/biotech/wh…

What does it mean for a confirmatory trial to be 'well underway'? Regeneron wants to know

Days after Regeneron received a complete response letter (CRL) for the blood cancer medicine odronextamab, hematology executive Andres Sirulnik, M.D., Ph.D., says the trial is enrolling just fine—i |...

fiercebiotech.com
239
Just imagine this: Every case of an important update being buried in an SEC filing is fed to an AI somewhere fiercebiotech.com/biotech/mo…

Moderna won't advance US-backed Zika vaccine without more outside funding

Moderna does not plan to advance a midstage Zika vaccine without additional outside cash, despite receiving U.S. funding thus far, according to a regulatory disclosure.  | Moderna does not plan to...

fiercebiotech.com
210
Angus Liu retweeted
FiercePharma
@FiercePharma
16 Jan 2024
Special report: CAR-T hype faces infrastructure reality check fiercepharma.com/pharma/mid-…

CAR-T hype faces infrastructure reality check

Since the FDA approved the first CAR-T therapy back in August 2017, high prices, small patients pools and limited manufacturing capacity have at times hindered these cell-based treatments. As...

fiercepharma.com
5
10
3,974
Angus Liu retweeted
FiercePharma
@FiercePharma
15 Nov 2023
Novo Nordisk answers Eli Lilly's challenge in obesity treatment with its own head-to-head trial for a Wegovy combination against Zepbound. Details in story. fiercepharma.com/pharma/novo…

Novo Nordisk fights back at Lilly with Wegovy combo trial against Zepbound in obesity

In response to an onslaught from Eli Lilly, Novo Nordisk is escalating the obesity market battle with a new head-to-head trial against its archrival. | In response to an onslaught from Eli Lilly,...

fiercepharma.com
1
8
9
4,114
Angus Liu retweeted
FiercePharma
@FiercePharma
16 Oct 2023
The FDA has approved Merck's Keytruda as part of a neoadjuvant-plus-adjuvant therapy for resectable non-small cell lung cancer. The label already includes overall survival data. fiercepharma.com/pharma/merc…

Merck’s Keytruda wins coveted FDA nod around surgery for early lung cancer—with a surprise

Up until this point, immune checkpoint inhibitors have been allowed to treat early-stage non-small cell lung cancer (NSCLC) either before or after surgery. | Thanks to a new FDA approval for Merck's...

fiercepharma.com
5
9
4,615
Angus Liu retweeted
FiercePharma
@FiercePharma
7 Sep 2023
In the Breakthroughs category, we’ll recognize organizations, clinicians, researchers and others whose work has pushed the boundaries of knowledge and improved the lives of countless individuals. fiercepharma.com/fierce-50/f… #Fierce50 #WeAreFierce

Fierce 50 spotlight: Breakthroughs category chair Eric Sagonowsky

The Breakthroughs category of the Fierce 50 features those who have made groundbreaking discoveries that have signi | The Breakthroughs category of the Fierce 50 features those who have made ground...

fiercepharma.com
5
9
4,273
Merck and Moderna's phase 3 plan for their mRNA cancer vaccine is here. $MRK $MRNA fiercebiotech.com/biotech/me…

Merck, Moderna unveil phase 3 trial details for closely watched mRNA cancer vaccine

After a major phase 2 win that stirred up much excitement within the oncology community, Merck & Co. | After a major phase 2 win that stirred up much excitement within the oncology community, Merck...

fiercebiotech.com
1
1
310
This week's The Top Line podcast from @FiercePharma includes a recap of the star-studded ADA meeting omny.fm/shows/the-top-line/j…

June 30, 2023 - The Top Line

In this episode of "The Top Line," we talk with Fierce’s Andrea Park and Gabrielle Masson about the latest from the American Diabetes Association's annual conference. We also cover a statement about...

omny.fm
254
Load more